将前列腺特异性抗原动力学整合至根治性前列腺切除术后挽救性放疗的当代预测列线图
多中心回顾性分析1005例根治性前列腺切除术后接受挽救性放疗的前列腺癌患者,中位随访5年。术后PSA动力学(尤其是放疗前PSA和PSA倍增时间)与生化失败、远处转移及前列腺癌特异性死亡显著相关,并据此构建了预测列线图。
要点
- PSA倍增时间<6个月与生化失败、远处转移及前列腺癌特异性死亡风险升高相关。
- 放疗前PSA水平与生化失败和远处转移风险独立相关。
- 基于PSA动力学等因子构建的列线图可预测生化失败、远处转移和前列腺癌特异性死亡。
核心结论
- 术后PSA动力学,特别是放疗前PSA和PSA倍增时间,与挽救性放疗后不良肿瘤学结局强相关,应纳入管理决策。
研究设计与样本
- 多中心回顾性分析纳入1005例根治性前列腺切除术后接受挽救性放疗的前列腺癌患者,中位随访5年。
- 采用Fine-Gray竞争风险回归进行多变量生存分析,并通过累积发生率法估计生化失败、远处转移和前列腺癌特异性死亡率。
- 列线图基于多变量竞争风险回归生成,并采用bootstrap交叉验证。
主要发现
- 与挽救性放疗后生化失败相关的因素包括PSA倍增时间<6个月、术后初始PSA≥0.2 ng/ml、较高的放疗前PSA、未接受雄激素剥夺治疗、较高的Gleason评分、切缘阴性、精囊侵犯、未接受盆腔淋巴结放疗、放疗总剂量<66 Gy、较长的根治性前列腺切除至挽救性放疗间隔以及年龄较大(每项p<0.05)。
- 与远处转移相关的因素包括PSA倍增时间<6个月、放疗前PSA、较高的Gleason评分和切缘阴性。
- 与前列腺癌特异性死亡相关的因素包括PSA倍增时间不可计算或<6个月以及较高的Gleason评分。
- 列线图预测生化失败的 concordance index(CI)为0.74,预测远处转移的CI为0.77,预测前列腺癌特异性死亡的CI为0.77。
关键数值与推荐
- PSA倍增时间<6个月、术后初始PSA≥0.2 ng/ml、较高的放疗前PSA、未接受雄激素剥夺治疗、较高的Gleason评分、切缘阴性、精囊侵犯、未接受盆腔淋巴结放疗、放疗总剂量<66 Gy、较长的根治性前列腺切除至挽救性放疗间隔以及年龄较大与生化失败风险升高相关(每项p<0.05)。
- PSA倍增时间<6个月、放疗前PSA、较高的Gleason评分和切缘阴性与远处转移风险升高相关。
- PSA倍增时间不可计算或<6个月以及较高的Gleason评分与前列腺癌特异性死亡风险升高相关。
临床怎么用
- 对于根治性前列腺切除术后生化复发拟行挽救性放疗的患者,应评估术后PSA动力学(包括PSA倍增时间和放疗前PSA)以辅助风险分层。
- 可利用基于PSA动力学等因子构建的列线图估算生化失败、远处转移和前列腺癌特异性死亡风险,辅助讨论是否增加放疗等治疗。
局限性
- 回顾性研究设计。
- 治疗年代跨度大。
- 存在机构间差异。
- PSA倍增时间估算方法多样。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Salvage radiotherapy (SRT) is an established treatment for men with biochemical recurrence following radical prostatectomy (RP). There are several risk factors associated with adverse outcomes; however, the value of postoperative prostate-specific antigen (PSA) kinetics is less clear in the ultrasensitive PSA era. OBJECTIVE: To characterize the impact of PSA kinetics on outcomes following SRT and generate nomograms to aid in identifying patients with an increased risk of adverse clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional analysis was conducted of 1005 patients with prostate cancer treated with SRT after RP, with a median follow-up of 5 years. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Variables examined include immediate postoperative PSA, postoperative PSA doubling time (DT), and pre-SRT PSA, in addition to previously identified predictive factors. Multivariable survival analyses were completed using Fine-Gray competing risk regression. Rates of biochemical failure (BF), distant metastasis (DM), and prostate cancer-specific mortality (PCSM) were estimated by the cumulative incidence method. Nomograms were generated from multivariable competing risk regression with bootstrap cross-validation. RESULTS AND LIMITATIONS: Factors associated with BF after SRT include PSA DT <6 mo, initial postoperative PSA ≥0.2 ng/ml, higher pre-SRT PSA, lack of androgen deprivation therapy, a higher Gleason score (GS), negative margins, seminal vesicle invasion, lack of pelvic nodal radiation, radiation total dose <66 Gy, a longer RP to SRT interval, and older age (p < 0.05 for each). Factors associated with DM include PSA DT <6 mo, pre-SRT PSA, a higher GS, and negative margins. Factors associated with PCSM include PSA DT not calculable or <6 mo and a higher GS. Nomograms were generated to estimate the risks of BF (concordance index [CI] 0.74), DM (CI 0.77), and PCSM (CI 0.77). Limitations include retrospective nature, broad treatment eras, institutional variations, and multiple methods available for the estimation of PSA DT. CONCLUSIONS: Postoperative PSA kinetics, particularly pre-SRT PSA and PSA DT, are strongly associated with adverse oncologic outcomes following SRT and should be considered in management decisions. PATIENT SUMMARY: In this report of men with prostate cancer who developed a prostate-specific antigen (PSA) recurrence after prostatectomy, we found that PSA levels after surgery and how quickly a PSA level doubles significantly impact the chance of prostate cancer recurrence after salvage radiation therapy. Based on this information, we created a tool to calculate a man's chance of cancer recurrence after salvage radiation therapy, and these estimations can be used to discuss whether additional treatment with radiation should be considered.
引用
- Campbell SR, Tom MC, Agrawal S, et al. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy. Eur Urol Oncol. 2021. PMID: 34016556. doi:10.1016/j.euo.2021.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。